Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1996 Sep 14;313(7058):652–659. doi: 10.1136/bmj.313.7058.652

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.

R Collins 1, S MacMahon 1, M Flather 1, C Baigent 1, L Remvig 1, S Mortensen 1, P Appleby 1, J Godwin 1, S Yusuf 1, R Peto 1
PMCID: PMC2351968  PMID: 8811758

Abstract

OBJECTIVES: Most randomised trials of anticoagulant therapy for suspected acute myocardial infarction have been small and, in some, aspirin and fibrinolytic therapy were not used routinely. A systematic overview (meta-analysis) of their results is needed, in particular to assess the clinical effects of adding heparin to aspirin. DESIGN: Computer aided searches, scrutiny of reference lists, and inquiry of investigators and companies were used to identify potentially eligible studies. On central review, 26 studies were found to involve unconfounded randomised comparisons of anticoagulant therapy versus control in suspected acute myocardial infarction. Additional information on study design and outcome was sought by correspondence with study investigators. SUBJECTS: Patients with suspected acute myocardial infarction. INTERVENTIONS: No routine aspirin was used among about 5000 patients in 21 trials (including half of one small trial) that assessed heparin alone or heparin plus oral anticoagulants, and aspirin was used routinely among 68,000 patients in six trials (including the other half of one small trial) that assessed the addition of intravenous or high dose subcutaneous heparin. MAIN OUTCOME MEASUREMENTS: Death, reinfarction, stroke, pulmonary embolism, and major bleeds (average follow up of about 10 days). RESULTS: In the absence of aspirin, anticoagulant therapy reduced mortality by 25% (SD 8%; 95% confidence interval 10% to 38%; 2P = 0.002), representing 35 (11) fewer deaths per 1000. There were also 10 (4) fewer strokes per 1000 (2P = 0.01), 19 (5) fewer pulmonary emboli per 1000 (2P < 0.001), and non-significantly fewer reinfarctions, with about 13 (5) extra major bleeds per 1000 (2P = 0.01). Similar sized effects were seen with the different anticoagulant regimens studied. In the presence of aspirin, however, heparin reduced mortality by only 6% (SD 3%; 0% to 10%; 2P = 0.03), representing just 5 (2) fewer deaths per 1000. There were 3 (1.3) fewer reinfarctions per 1000 (2P = 0.04) and 1 (0.5) fewer pulmonary emboli per 1000 (2P = 0.01), but there was a small non-significant excess of stroke and a definite excess of 3 (1) major bleeds per 1000 (2P < 0.0001). CONCLUSIONS: The clinical evidence from randomised trials dose not justify the routine addition of either intravenous or subcutaneous heparin to aspirin in the treatment of acute myocardial infarction (irrespective of whether any type of fibrinolytic therapy is used).

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman E. M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994 Oct;90(4):1624–1630. doi: 10.1161/01.cir.90.4.1624. [DOI] [PubMed] [Google Scholar]
  2. Arnout J., Simoons M., de Bono D., Rapold H. J., Collen D., Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 1992 Sep;20(3):513–519. doi: 10.1016/0735-1097(92)90001-4. [DOI] [PubMed] [Google Scholar]
  3. Arvan S., Boscha K. Prophylactic anticoagulation for left ventricular thrombi after acute myocardial infarction: a prospective randomized trial. Am Heart J. 1987 Mar;113(3):688–693. doi: 10.1016/0002-8703(87)90708-3. [DOI] [PubMed] [Google Scholar]
  4. BJERKELUND C. J. The effect of long term treatment with dicoumarol in myocardial infarction; a controlled clinical study. Acta Med Scand Suppl. 1957;330:1–212. [PubMed] [Google Scholar]
  5. BROWN K. W., MACMILLAN R. L. INITIAL HEPARIN THERAPY IN ACUTE MYOCARDIAL INFARCTION. Can Med Assoc J. 1964 Jun 13;90:1345–1348. [PMC free article] [PubMed] [Google Scholar]
  6. Bleich S. D., Nichols T. C., Schumacher R. R., Cooke D. H., Tate D. A., Teichman S. L. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990 Dec 15;66(20):1412–1417. doi: 10.1016/0002-9149(90)90525-6. [DOI] [PubMed] [Google Scholar]
  7. Chalmers T. C., Matta R. J., Smith H., Jr, Kunzler A. M. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med. 1977 Nov 17;297(20):1091–1096. doi: 10.1056/NEJM197711172972004. [DOI] [PubMed] [Google Scholar]
  8. Collins R., Gray R., Godwin J., Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med. 1987 Apr-May;6(3):245–254. doi: 10.1002/sim.4780060308. [DOI] [PubMed] [Google Scholar]
  9. Collins R., Scrimgeour A., Yusuf S., Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988 May 5;318(18):1162–1173. doi: 10.1056/NEJM198805053181805. [DOI] [PubMed] [Google Scholar]
  10. Cruickshank M. K., Levine M. N., Hirsh J., Roberts R., Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med. 1991 Feb;151(2):333–337. [PubMed] [Google Scholar]
  11. Davis M. J., Ireland M. A. Effect of early anticoagulation on the frequency of left ventricular thrombi after anterior wall acute myocardial infarction. Am J Cardiol. 1986 Jun 1;57(15):1244–1247. doi: 10.1016/0002-9149(86)90196-7. [DOI] [PubMed] [Google Scholar]
  12. Drapkin A., Merskey C. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. JAMA. 1972 Oct 30;222(5):541–548. doi: 10.1001/jama.222.5.541. [DOI] [PubMed] [Google Scholar]
  13. Díaz R., Torres H. Valor de la anticoagulación precoz en la prevención de la trombosis intraventricular después de un primer infarto del miocardio: estudio prospectivo y randomizado. Rev Med Chil. 1988 Jan;116(1):13–17. [PubMed] [Google Scholar]
  14. Ellerbeck E. F., Jencks S. F., Radford M. J., Kresowik T. F., Craig A. S., Gold J. A., Krumholz H. M., Vogel R. A. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995 May 17;273(19):1509–1514. [PubMed] [Google Scholar]
  15. Emerson P. A., Marks P. Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. Br Med J. 1977 Jan 1;1(6052):18–20. doi: 10.1136/bmj.1.6052.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gallus A. S., Hirsh J., Tutle R. J., Trebilcock R., O'Brien S. E., Carroll J. J., Minden J. H., Hudecki S. M. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med. 1973 Mar 15;288(11):545–551. doi: 10.1056/NEJM197303152881103. [DOI] [PubMed] [Google Scholar]
  17. Gueret P., Dubourg O., Ferrier A., Farcot J. C., Rigaud M., Bourdarias J. P. Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction. J Am Coll Cardiol. 1986 Aug;8(2):419–426. doi: 10.1016/s0735-1097(86)80061-4. [DOI] [PubMed] [Google Scholar]
  18. HARVALD B., HILDEN T., LUND E. Long-term anticoagulant therapy after myocardial infarction. Lancet. 1962 Sep 29;2(7257):626–630. doi: 10.1016/s0140-6736(62)92540-0. [DOI] [PubMed] [Google Scholar]
  19. Habersberger P. G., Pitt A., Anderson S. T. Venous thromboses in myocardial infarction. Comparison in heparin dosage. Br Heart J. 1973 May;35(5):538–542. doi: 10.1136/hrt.35.5.538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Handley A. J., Emerson P. A., Fleming P. R. Heparin in the prevention of deep vein thrombosis after myocardial infarction. Br Med J. 1972 May 20;2(5811):436–438. doi: 10.1136/bmj.2.5811.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Handley A. J. Low-dose heparin after myocardial infarction. Lancet. 1972 Sep 23;2(7778):623–624. doi: 10.1016/s0140-6736(72)93016-4. [DOI] [PubMed] [Google Scholar]
  22. Hennekens C. H., O'Donnell C. J., Ridker P. M. Current and future perspectives on antithrombotic therapy of acute myocardial infarction. Eur Heart J. 1995 Jul;16 (Suppl 500):2–9. doi: 10.1093/eurheartj/16.suppl_d.2. [DOI] [PubMed] [Google Scholar]
  23. Hirsh J., Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation. 1994 Mar;89(3):1449–1468. doi: 10.1161/01.cir.89.3.1449. [DOI] [PubMed] [Google Scholar]
  24. Hsia J., Hamilton W. P., Kleiman N., Roberts R., Chaitman B. R., Ross A. M. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med. 1990 Nov 22;323(21):1433–1437. doi: 10.1056/NEJM199011223232101. [DOI] [PubMed] [Google Scholar]
  25. Loeliger E. A., Hensen A., Kroes F., van Dijk L. M., Fekkes N., de Jonge H., Hemker H. C. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand. 1967 Nov;182(5):549–566. doi: 10.1111/j.0954-6820.1967.tb10881.x. [DOI] [PubMed] [Google Scholar]
  26. Lovell R. R., Denborough M. A., Nestel P. J., Goble A. J. A controlled trial of long-term treatment with anticoagulants after myocardial infarction in 412 male patients. Med J Aust. 1967 Jul 15;2(3):97–104. doi: 10.5694/j.1326-5377.1967.tb73912.x. [DOI] [PubMed] [Google Scholar]
  27. MACMILLAN R. L., BROWN K., WATT D. L. Long-term anticoagulant therapy after myocardial infarction. Can Med Assoc J. 1960 Sep 10;83:567–570. [PMC free article] [PubMed] [Google Scholar]
  28. Mahaffey K. W., Granger C. B., Collins R., O'Connor C. M., Ohman E. M., Bleich S. D., Col J. J., Califf R. M. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. 1996 Mar 15;77(8):551–556. doi: 10.1016/s0002-9149(97)89305-8. [DOI] [PubMed] [Google Scholar]
  29. Neuhaus K. L., von Essen R., Tebbe U., Jessel A., Heinrichs H., Mäurer W., Döring W., Harmjanz D., Kötter V., Kalhammer E. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Circulation. 1994 Oct;90(4):1638–1642. doi: 10.1161/01.cir.90.4.1638. [DOI] [PubMed] [Google Scholar]
  30. Nordrehaug J. E., Johannessen K. A., von der Lippe G. Usefulness of high-dose anticoagulants in preventing left ventricular thrombus in acute myocardial infarction. Am J Cardiol. 1985 Jun 1;55(13 Pt 1):1491–1493. doi: 10.1016/0002-9149(85)90959-2. [DOI] [PubMed] [Google Scholar]
  31. Peto R. Why do we need systematic overviews of randomized trials? Stat Med. 1987 Apr-May;6(3):233–244. doi: 10.1002/sim.4780060306. [DOI] [PubMed] [Google Scholar]
  32. Pitt A., Anderson S. T., Habersberger P. G., Rosengarten D. S. Low dose heparin in the prevention of deep-vein thromboses in patients with acute myocardial infarction. Am Heart J. 1980 May;99(5):574–578. doi: 10.1016/0002-8703(80)90729-2. [DOI] [PubMed] [Google Scholar]
  33. Prandoni P., Russo R., Pengo V., Boschello M., Casara D., Maddalena F., Schivazappa L. Prevenzione della trombosi venosa profonda con eparina a basse dosi in pazienti con infarto miocardico acuto non complicato. Studio in doppio cieco controllato. Minerva Cardioangiol. 1986 Oct;34(10):653–657. [PubMed] [Google Scholar]
  34. Remvig L., Mortensen S. A., Als O. S., Mentzel V., Holm G. Lav-dosis heparinbehandling som profylakse mod dyb venetrombose ved akut myokardieinfarkt. En kontrolleret klinisk undersøgelse. Ugeskr Laeger. 1983 Apr 4;145(14):1053–1056. [PubMed] [Google Scholar]
  35. Ridker P. M., Hebert P. R., Fuster V., Hennekens C. H. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet. 1993 Jun 19;341(8860):1574–1577. doi: 10.1016/0140-6736(93)90707-n. [DOI] [PubMed] [Google Scholar]
  36. Ruggiero H. A., Caprissi L. F., Neuman J., de Caprissi E. S. Treatment of acute myocardial infarction with subcutaneous heparin at low doses. Clin Cardiol. 1987 Oct;10(10):598–602. doi: 10.1002/clc.4960101018. [DOI] [PubMed] [Google Scholar]
  37. Sorensen O. H., Friis T., Jorgensen A. W., Jorgensen M. B., Nissen N. I. Anticoagulant treatment of acute coronary thrombosis. Acta Med Scand. 1969 Jan-Feb;185(1-2):65–72. doi: 10.1111/j.0954-6820.1969.tb07299.x. [DOI] [PubMed] [Google Scholar]
  38. Steffensen K. A. Coronary occlusion treated with small doses of heparin. Acta Med Scand. 1969 Dec;186(6):519–521. doi: 10.1111/j.0954-6820.1969.tb01515.x. [DOI] [PubMed] [Google Scholar]
  39. Topol E. J., George B. S., Kereiakes D. J., Stump D. C., Candela R. J., Abbottsmith C. W., Aronson L., Pickel A., Boswick J. M., Lee K. L. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation. 1989 Feb;79(2):281–286. doi: 10.1161/01.cir.79.2.281. [DOI] [PubMed] [Google Scholar]
  40. Turpie A. G., Robinson J. G., Doyle D. J., Mulji A. S., Mishkel G. J., Sealey B. J., Cairns J. A., Skingley L., Hirsh J., Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989 Feb 9;320(6):352–357. doi: 10.1056/NEJM198902093200604. [DOI] [PubMed] [Google Scholar]
  41. VAKIL R. J. PREINFARCTION SYNDROME--MANAGEMENT AND FOLLOW-UP. Am J Cardiol. 1964 Jul;14:55–63. doi: 10.1016/0002-9149(64)90106-7. [DOI] [PubMed] [Google Scholar]
  42. Van de Werf F., Topol E. J., Lee K. L., Woodlief L. H., Granger C. B., Armstrong P. W., Barbash G. I., Hampton J. R., Guerci A., Simes R. J. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. JAMA. 1995 May 24;273(20):1586–1591. doi: 10.1001/jama.273.20.1586. [DOI] [PubMed] [Google Scholar]
  43. Warlow C., Terry G., Kenmure A. C., Beattie A. G., Ogston D., Douglas A. S. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet. 1973 Oct 27;2(7835):934–936. doi: 10.1016/s0140-6736(73)92597-x. [DOI] [PubMed] [Google Scholar]
  44. Wasserman A. J., Gutterman L. A., Yoe K. B., Kemp V. E., Jr, Richardson D. W. Anticoagulants in acute myocardial infarction. The failure of anticoagulants to alter mortality in a randomized series. Am Heart J. 1966 Jan;71(1):43–49. doi: 10.1016/0002-8703(66)90655-7. [DOI] [PubMed] [Google Scholar]
  45. Wray R., Maurer B., Shillingford J. Prophylactic anticoagulant therapy in the prevention of calf-vein thrombosis after myocardial infarction. N Engl J Med. 1973 Apr 19;288(16):815–817. doi: 10.1056/NEJM197304192881604. [DOI] [PubMed] [Google Scholar]
  46. Zawilska K., Psuja P., Lewandowski K., Wróz M. Low-dose heparin in the prevention of thrombotic complications following acute myocardial infarction. Cor Vasa. 1989;31(3):179–185. [PubMed] [Google Scholar]
  47. de Bono D. P., Simoons M. L., Tijssen J., Arnold A. E., Betriu A., Burgersdijk C., López Bescos L., Mueller E., Pfisterer M., Van de Werf F. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J. 1992 Feb;67(2):122–128. doi: 10.1136/hrt.67.2.122. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES